AtheroGenics , Phase III clinical trial of AGI-1067, a Novel Anti-Diabetic Agent

AtheroGenics, Inc. (NASDAQ: AGIX), August 23, 2007, announced enrollment of the first patients in ANDES. ANDES (ANDES's PDF (1 page)) is a Phase III clinical trial of AGI-1067, an investigational first-in-class oral anti-diabetic agent with anti-inflammatory and antioxidant properties... The AtheroGenics' Press Release.